GENFIT Appoints Dr. Pejvack Motlagh As Chief Medical Officer To Lead Clinical Strategy In Rare Liver Diseases

GENFIT, a biopharmaceutical company focused on improving outcomes for patients with rare and life-threatening liver diseases, has announced the appointment of Dr. Pejvack Motlagh as its new Chief Medical Officer. As a member of the Executive Committee, Dr. Motlagh will lead GENFIT’s clinical strategy and oversee the execution of its development programs, guiding the Clinical Operations and Strategy, Biometrics, and Pharmacovigilance teams. Dr. Motlagh brings over two decades of experience in the pharmaceutical and biotechnology sectors, with extensive expertise in shaping development strategies across a wide range of therapeutic areas. 

His appointment strengthens GENFIT’s leadership at a time when the company is advancing multiple programs in high unmet-need liver indications. Before joining GENFIT, Dr. Motlagh served as Chief Medical Officer at Egle Therapeutics, where he helped drive the development of therapies targeting regulatory T cells for oncology and autoimmune diseases. He also held the CMO role at Mablink Biosciences, a company specializing in next-generation antibody-drug conjugates (ADCs). Earlier in his career, he occupied various leadership and clinical development roles within major global pharmaceutical companies, contributing to the progression of drug candidates from early-stage clinical trials through to commercialization.

Expressing his enthusiasm for the role, Dr. Motlagh noted that GENFIT is entering a critical period, especially as Acute-on-Chronic Liver Failure gains increasing attention within the medical community. He emphasized that the company’s dedication to science-driven innovation and patient-centered development closely aligns with his own values. He also highlighted his eagerness to collaborate with the GENFIT team to advance clinical programs aimed at addressing urgent and underserved medical needs.

GENFIT’s CEO, Pascal Prigent, welcomed the appointment, emphasizing Dr. Motlagh’s substantial experience and leadership across both established pharmaceutical companies and pioneering biotech organizations. He stated that Dr. Motlagh’s clinical development expertise will play an essential role in advancing GENFIT’s pipeline and furthering the company’s mission to deliver transformative therapies to patients facing serious liver diseases. With this leadership addition, GENFIT continues to strengthen its capabilities as it works toward developing meaningful solutions for complex liver conditions and expanding its impact within the rare disease landscape.